

Keen Eye raises €1.5 million from Seventure Partners' Quadrivium 1 seed fund

Keen Eye will finalize the development of its innovative image interpretation platform for laboratories and biomedical research.

Paris, December 12th 2016 - Keen Eye, a company that designs, develops and markets innovative image analysis solutions for research and the medical sector, announced today a €1.5 million fund raising from Seventure Partners' Quadrivium seed fund.

Thanks to this financing, the company will develop its Keen Eye image interpretation platform for the digital pathology market, marketed as a Software-as-a-Service (SaaS) offer. It allows users to share, view and analyze all types of biological samples, using innovative image processing and artificial intelligence algorithms, from anywhere and on any device (laptop, tablet, smartphone).

According to Sylvain Berlemont, Founder and President of Keen Eye, "*biomedical research is severely lacking in solutions for digital automation. Many activities carried out daily in pathology and research labs, or in contract-research organizations, are extremely time-consuming and often conducted by hand. Screening huge histological images in search of isolated tumor cells is usually similar to looking for a needle in a haystack, in a very limited time. This is particularly true for extemporaneous examinations where time is a key factor. Thanks to our interpretation platform, doctors and scientists will save a considerable amount of time for the benefit of patients and biomedical research.*"

According to Philippe Tramoy, Partner at the Quadrivium 1 seed fund, "*the images overwhelm academic laboratories, producing a mass of information for which the existing analytical tools are obsolete. The innovative platform from Keen Eye has all the features to revolutionize the routine analysis of images.*"

About Keen Eye

Founded in 2013, Keen Eye is a technology start-up that offers innovative image analysis solutions. Its mission is to support industrial and academic players of the health sector towards a broader use of automated analysis of visual data for the benefit of researchers, practitioners and patients.

To learn more, go to www.keeneye.tech

About Seventure Partners

As an active partner of innovative companies with high growth potential, Seventure Partners has been investing since 1997 in two main areas of activity: Digital technologies, particularly fintech and assurtech, in France, Germany and Luxembourg, and Life Sciences Throughout Europe and North America. Managing more than € 600 million as of December 31st 2015, Seventure Partners is emerging as one of Europe's leading innovation capital players. Seventure Partners has supported the development of companies from the first round and even the seeding, up to technological capital development financing rounds with tickets from € 500K to € 10m per financing round and up to € 20m per company. Seventure Partners is a subsidiary of Natixis Global Asset Management. Natixis is the finance, management and financial services arm of Groupe BPCE.

To learn more, go to www.seventure.fr

About the seed fund Quadrivium 1

The Quadrivium 1 Seed Fund is one of the capital-innovation funds managed by Seventure Partners. This fund finances French companies in the start-up phase (FNA - Program d'Investissement d'Avenir) in the fields of life sciences and digital technologies, which come from or are linked to the academic center federated around UPMC, University Paris II, the National Museum of Natural History, IRCAM, ENSCI, Technological University of Compiègne, CNRS, Institut Curie, Fondation Pierre Gilles de Gennes, Fondation Voir et Entendre and Paris Science and Letters (PSL).

Contacts

Keen Eye:

Sylvain Berlemont

sylvain.berlemont@keeneye.tech

+ 33 6 37 08 86 68

Media – NewCap:

Annie-Florence Loyer

afloyer@newcap.fr

+ 33 1 44 71 02 12 / +33 6 88 20 35 59

Seventure Partners' Quadrivium 1 seed fund:

Raïssa Brian

raissa.brian@seventure.fr

+ 33 1 58 19 33 56

Philippe Tramoy

philippe.tramoy@seventure.fr

+ 33 1 58 19 83 26